Risk Assessment in Quality by Design (QbD) Approach for Oral Solid Dosage Forms

Author's name: Bharat Patidar (M.PHARM, 3RD SEM, PACIFIC COLLEGE OF PHARMACY)

Guided by: Dr. Deepak Sharma (PROFESSOR, PACIFIC COLLEGE OF PHARMACY)

Abstract

Quality by Design (QbD) is a systematic, science- and risk-based approach to pharmaceutical development that emphasizes designing quality into products rather than relying solely on end-product testing. Risk assessment is a fundamental component of the QbD framework and plays a decisive role in identifying, analyzing, and controlling sources of variability that may impact product quality. Oral solid dosage forms (OSDFs), such as tablets and capsules, involve complex interactions between formulation components and manufacturing processes, making them particularly sensitive to material and process-related risks. This review comprehensively discusses the application of risk assessment within the QbD framework for OSDFs, including regulatory expectations, quality risk management principles, critical quality attributes, commonly used risk assessment tools, formulation and process risks, control strategies, and lifecycle management. The integration of structured risk assessment with QbD enhances process robustness, regulatory flexibility, and patient safety.

Keywords

Quality by Design; Risk Assessment; Oral Solid Dosage Forms; Critical Quality Attributes; Quality Risk Management; ICH Guidelines

1. Introduction

Oral solid dosage forms represent the most widely used pharmaceutical dosage forms owing to their convenience, patient compliance, stability, and economic manufacturing advantages [1,2]. Despite these benefits, ensuring consistent quality of OSDFs is challenging due to the inherent complexity of formulation components and the multistep nature of manufacturing processes [3].

Traditionally, pharmaceutical development relied on empirical approaches and extensive end-product testing to assure quality. This "quality by testing" strategy often resulted in limited process understanding and frequent batch failures [4]. To overcome these

limitations, regulatory authorities have promoted the adoption of Quality by Design, a systematic approach that integrates scientific knowledge and quality risk management into pharmaceutical development [5].

The QbD concept has been formalized through guidelines issued by the International Council for Harmonisation, particularly ICH Q8, ICH Q9, and ICH Q10 [6–8]. Among these, risk assessment serves as the backbone for identifying critical variables and ensuring robust product quality throughout the lifecycle.

2. Concept of Quality by Design (QbD)

Quality by Design is defined as a systematic approach to pharmaceutical development that begins with predefined objectives and emphasizes product and process understanding based on sound science and quality risk management [6]. The core principle of QbD is that quality should be proactively built into the product rather than tested into it.

2.1 Key Elements of QbD

The QbD framework consists of interrelated elements that collectively ensure product quality:

•Quality Target Product Profile (QTPP): A prospective summary of desired quality characteristics of the finished dosage form, including dosage strength, release characteristics, and stability [6].

•Critical Quality Attributes (CQAs): Physical, chemical, biological, or microbiological attributes that must be controlled to ensure product quality.

•Critical Material Attributes (CMAs): Properties of raw materials, including API and excipients, that influence CQAs.

•Critical Process Parameters (CPPs): Process variables that have a direct and significant impact on CQAs.

•Design Space: The multidimensional combination of CMAs and CPPs that assures product quality.

•Control Strategy: A planned set of controls derived from product and process understanding.

Risk assessment provides the scientific rationale for identifying CQAs, CMAs, and CPPs and for establishing an appropriate control strategy.

3. Importance of Risk Assessment in QbD

Risk assessment is a structured process used to identify potential hazards and evaluate the likelihood and severity of their impact on product quality [7]. Within the QbD framework, risk assessment enables efficient prioritization of variables that require detailed investigation.

The main objectives of risk assessment in pharmaceutical QbD include:

- Identification of sources of variability that may affect CQAs
- Prioritization of formulation and process variables
- Rational design of experimental studies
- Reduction in development time and cost
- Enhancement of process robustness and reproducibility [9,10]

For OSDFs, risk assessment is particularly important due to the cumulative impact of multiple unit operations on final product quality.

4. Quality Risk Management Framework

Quality risk management, as described in ICH Q9, is a systematic process comprising risk identification, risk analysis, and risk evaluation, followed by risk control and review [7].

4.1 Risk Identification

Risk identification involves systematic recognition of potential factors that may adversely affect product quality. For OSDFs, these may include:

- API physicochemical properties
- Excipient variability
- Equipment design and scale
- Environmental conditions such as temperature and humidity [11]

4.2 Risk Analysis

Risk analysis involves estimating the probability of occurrence and severity of each identified risk. Depending on data availability, qualitative or semi-quantitative approaches may be employed [12].

4.3 Risk Evaluation

Risk evaluation compares analyzed risks against predefined acceptance criteria to determine whether risk reduction measures are required.

5. Critical Quality Attributes (CQAs) for Oral Solid Dosage Forms

Critical Quality Attributes are measurable properties that must be controlled to ensure the desired quality, safety, and efficacy of the drug product [6].

Common CQAs for OSDFs

- •Assay and content uniformity
- •Dissolution and drug release profile
- •Disintegration time
- •Tablet hardness and friability
- •Moisture content
- •Stability and impurity profile [13,14]

Identification of CQAs forms the basis for subsequent risk assessment and experimental design.

6. Risk Assessment Tools Used in QbD



6.1 Failure Mode and Effects Analysis (FMEA)

FMEA is one of the most widely used tools in pharmaceutical risk assessment. It evaluates potential failure modes, their causes, and their effects on product quality. Risks are scored based on severity, occurrence, and detectability to generate a Risk Priority Number (RPN) [15].

6.2 Ishikawa (Fishbone) Diagram

Ishikawa diagrams facilitate comprehensive identification of potential risk factors by categorizing them under materials, methods, machines, manpower, measurement, and environment [16].

6.3 Hazard Analysis and Critical Control Points (HACCP)

HACCP identifies critical control points within manufacturing processes where control is essential to prevent quality failures [17].

6.4 Risk Ranking and Filtering

This tool is useful during early development stages to prioritize numerous variables when experimental data are limited.

7. Risk Assessment in Formulation Development of OSDFs

7.1 API-Related Risks

API characteristics such as particle size distribution, polymorphism, solubility, flowability, and hygroscopicity can significantly influence blend uniformity, dissolution behavior, and stability [18].

7.2 Excipient-Related Risks

Excipients play functional roles in OSDFs, and variability in their properties can affect CQAs. For example, binder concentration influences tablet hardness and disintegration, while lubricant level can impact dissolution and content uniformity [19].

7.3 Blend Uniformity Risks

Segregation caused by differences in particle size, density, or shape may result in content non-uniformity, particularly in low-dose formulations [20].

8. Risk Assessment in Manufacturing Processes



Fig.no.2 Tablet manufacturing process

8.1 Granulation Process

Key risks include binder addition rate, granule moisture content, and drying conditions, all of which influence granule strength and compressibility [21].

8.2 Compression Process

Compression force, dwell time, and tooling design are critical process parameters affecting tablet hardness, friability, and dissolution [22].

8.3 Coating Process

Coating-related risks involve spray rate, inlet air temperature, and pan speed, which can influence coating uniformity and drug release characteristics [23].

9. Risk Control Strategies

Risk control involves reducing or eliminating identified risks through formulation optimization, establishment of design space, implementation of Process Analytical Technology (PAT), and robust in-process controls [24].

10. Lifecycle Management and Continuous Improvement

Risk assessment is a dynamic process that continues throughout the product lifecycle. Continuous monitoring of process performance and quality trends supports ongoing risk review, change management, and continual improvement [25].

11. Regulatory Perspective

Regulatory agencies encourage QbD-based submissions as they demonstrate enhanced understanding of product and process variability. A well-documented risk assessment supports regulatory confidence and provides flexibility for post-approval changes within the approved design space [26].

12. Future Perspectives

Advances in data analytics, modeling, artificial intelligence, and real-time monitoring tools are expected to strengthen risk-based QbD approaches, enabling predictive risk assessment and improved control of OSDF manufacturing processes [27].

13. Conclusion

Risk assessment is the cornerstone of the Quality by Design approach for oral solid dosage forms. Systematic identification, analysis, and control of formulation and process-related risks ensure consistent product quality, regulatory compliance, and improved patient outcomes. Integration of structured risk assessment tools within the QbD framework represents a robust and sustainable strategy for modern pharmaceutical development.

References

1. Aulton ME, Taylor KMG. Aulton's Pharmaceutics: The Design and Manufacture of Medicines. 5th ed. Elsevier; 2018.

2. Banker GS, Anderson NR. Tablets. In: Lachman L, Lieberman HA, Kanig JL, editors. The Theory and Practice of Industrial Pharmacy. CBS Publishers; 2013.

3. Yu LX. Pharmaceutical quality by design: product and process development, understanding, and control. Pharm Res. 2008;25(4):781–791.

4. Nasr M. Implementation of quality by design (QbD): status, challenges, and next steps. AAPS J. 2011;13(3):591–603.

5. FDA. Pharmaceutical cGMPs for the 21st Century—A Risk-Based Approach. US FDA; 2004.

6. ICH. Q8(R2): Pharmaceutical Development. International Council for Harmonisation; 2009.

7. ICH. Q9: Quality Risk Management. International Council for Harmonisation; 2005.

8. ICH. Q10: Pharmaceutical Quality System. International Council for Harmonisation; 2008.

9. Lawrence XY, Amidon G. Understanding pharmaceutical quality. J Pharm Sci. 2014;103(2):324–331.

10. Rathore AS, Winkle H. Quality by design for biopharmaceuticals. Nat Biotechnol. 2009;27(1):26–34.

11. Crowley P, Martini LG. Drug–excipient interactions. Drug Dev Ind Pharm. 2001;27(4):355–363.

12. ISO 31000. Risk Management—Principles and Guidelines. International Organization for Standardization; 2018.

13. United States Pharmacopeia. USP–NF General Chapters. USP Convention; 2023.

14. Allen LV, Ansel HC. Pharmaceutical Calculations. 14th ed. Lippincott Williams & Wilkins; 2016.

15. Stamatis DH. Failure Mode and Effect Analysis: FMEA from Theory to Execution. ASQ Press; 2003.

16. Ishikawa K. Guide to Quality Control. Asian Productivity Organization; 1986.

17. Mortimore S, Wallace C. HACCP: A Practical Approach. Springer; 2013.

18. Brittain HG. Polymorphism in pharmaceutical solids. Drugs Pharm Sci. 2009;192:1–21.

19. Rowe RC, Sheskey PJ, Quinn ME. Handbook of Pharmaceutical Excipients. 7th ed. Pharmaceutical Press; 2012.

20. Prescott JK, Barnum RA. On powder flowability. Pharm Technol. 2000;24(10):60–84.

21. Parikh DM. Handbook of Pharmaceutical Granulation Technology. 3rd ed. CRC Press; 2016.

22. Alderborn G, Nyström C. Pharmaceutical Powder Compaction Technology. Marcel Dekker; 1996.

23. Porter SC. Coating of Pharmaceutical Dosage Forms. Remington: The Science and Practice of Pharmacy; 2017.

24. Bakeev KA. Process Analytical Technology. Blackwell Publishing; 2010.

25. FDA. Process Validation: General Principles and Practices. US FDA; 2011.

26. EMA. Guideline on the Use of QbD in Pharmaceutical Development. European Medicines Agency; 2017.

27. Garcia-Muñoz S, et al. Data analytics and digitalization in pharmaceutical manufacturing. J Pharm Innov. 2020;15:1–15.